retatrutide glp1 a vs. Ozempic: The Triple Agonist That May Change Everything., Semaglutide hits one receptor. Retatrutide hits three., That difference may be the biggest leap in metabolic medicine since , Retatrutide, an experimental weight-loss drug,

If you have a planned major surgery requiring sedation, reach out to your provider for instructions on what to do

GLP 1 receptor agonists and dual incretin therapies are delivering measurable, outcome driven results: 12% to 27% relative risk reduction in major adverse cardiovascular events across CVOTs 13% to 14% reduction in cardiovascular death in meta analyses 11% to 14% reduction in hospitalization for heart failure 24% relative risk reduction in kidney outcomes in the dedicated FLOW trial with semaglutide Up to 15.8% weight loss with semaglutide 2.4 mg 20.2% weight loss with tirzepatide 15 mg in head to head obesity trials 66% to 93% reduction in progression from prediabetes to type 2 diabetes This is no longer about glucose (or weight loss) alone

honoraria from Amgen, Besins, CDD, Kyowa Kirin, and Theramex

Bottom line The essence of microdosing semaglutide is to find the most effective, lowest dose for you, minimize side effects, and achieve lasting metabolic improvements

Nutrition and Workout Timing Exercise creates specific nutritional demands that conflict with Retatrutides appetite suppression